Ep. 253, Chapter 2: The Art Of The Biotech Pivot with Mark Eisner, MD

14:20-22:11

Dr. Eisner explains how Vir’s Technology’s pivot from infectious disease to include oncology is more substantial than a large company reshuffling its portfolio, highlighting the thematic connection through the immune system and the foundational role of antibody engineering at Vir. He also details Vir's two distinct platforms: the dAIsY™ platform, an AI-driven tool for accelerating and optimizing antibody engineering, and the PRO-XTEN™ platform, a masking technology for T-cell engagers designed to improve efficacy and safety. Both platforms are considered complementary and are continuously refined.